Therapeutic options for metastatic breast cancer

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

(2017) J. O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic breast cancer (MBC): FDA approval overview

(2017) P. Cortazar et al.   JOURNAL OF CLINICAL ONCOLOGY

Do clinical practice guidelines (CPGs) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer

(2017) B. J. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan

(2009) Nahomi Tokudome et al.   ANTI-CANCER DRUGS

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer

(2008) Rupert Bartsch et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase II Study of Weekly Vinorelbine and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer

(2008) Juan Lucas Bayo-Calero et al.   Clinical Breast Cancer

Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer

(2008) Tiffany A. Traina et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

(2008) Kathy S. Albain et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines

(2008) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY